ALLO

Revenue: As of FY2026 Q3, the actual value is USD 0.

EPS: As of FY2026 Q3, the actual value is USD -0.15, compared to the market estimate of USD -0.1471.

EBIT: As of FY2026 Q3, the actual value is USD -49.91 M.

Financial Results for the Three Months Ended September 30, 2026, and 2025

Operating Expenses

• Research and development expenses were $41,934 thousand for Q3 2026, compared to $31,164 thousand for Q3 2025. This included $2.9 million of non-cash stock-based compensation expense for Q3 2026.
• General and administrative expenses were $12,859 thousand for Q3 2026, compared to $13,737 thousand for Q3 2025. This included $4.2 million of non-cash stock-based compensation expense for Q3 2026.
• Total operating expenses were $54,793 thousand for Q3 2026, compared to $44,901 thousand for Q3 2025.

Profitability

• Loss from operations was - $54,793 thousand for Q3 2026, compared to - $44,901 thousand for Q3 2025.
• Net loss was - $50,369 thousand for Q3 2026, compared to - $41,400 thousand for Q3 2025. This figure included total non-cash stock-based compensation expense of $7.0 million for Q3 2026.

Other Income/Expenses

• Net interest and other income was $4,879 thousand for Q3 2026, compared to $3,926 thousand for Q3 2025.
• Interest expense was - $379 thousand for Q3 2026, compared to - $344 thousand for Q3 2025.
• Other income (expenses), net, was - $76 thousand for Q3 2026, compared to - $81 thousand for Q3 2025.
• Total other income (expenses), net, was $4,424 thousand for Q3 2026, compared to $3,501 thousand for Q3 2025.

Selected Balance Sheet Data

Cash and Investments

• Cash, cash equivalents and investments totaled $388,873 thousand as of September 30, 2026, compared to $258,253 thousand as of December 31, 2025.

Assets and Liabilities

• Total assets were $511,320 thousand as of September 30, 2026, compared to $415,905 thousand as of December 31, 2025.
• Total liabilities were $118,768 thousand as of September 30, 2026, compared to $123,363 thousand as of December 31, 2025.
• Total stockholders’ equity was $392,552 thousand as of September 30, 2026, compared to $292,542 thousand as of December 31, 2025.

Outlook / Guidance

Allogene Therapeutics, Inc. expects its next ALPHA3 clinical update in mid-2027, with trial enrollment anticipated to conclude by year-end 2027. The company projects its cash runway will extend into 2029. Total operating expenses for 2026 are estimated to be approximately $165 million, with GAAP Operating Expenses at $225 million, including about $35 million in non-cash stock-based compensation.